Veronica Vernier

Via Rita Levi Montalcini 4, Pieve Emanuele
Milan, 20072, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Adjuvant stereotactic pancreatic radiotherapy (SPARTA trial): interim safety analysis of an ongoing phase II single center prospective study.

Adjuvant stereotactic pancreatic radiotherapy (SPARTA trial): interim safety analysis of an ongoing phase II single center prospective study.

Journal: Radiation oncology (London, England)

Published: December 03, 2025

Stereotactic ablative radiotherapy: an effective alternative for pancreatic metastases originating from renal cell carcinoma-experience from two European institutions.

Stereotactic ablative radiotherapy: an effective alternative for pancreatic metastases originating from renal cell carcinoma-experience from two European institutions.

Journal: Clinical & experimental metastasis

Published: September 22, 2025

Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR).

Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR).

Journal: Cancers

Published: June 02, 2024

Adjuvant Hypofractionated Whole Breast Irradiation (WBI) vs. Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5Years Update of the HYPAB Trial.

Adjuvant Hypofractionated Whole Breast Irradiation (WBI) vs. Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5Years Update of the HYPAB Trial.

Journal: Clinical breast cancer

Published: October 12, 2023

Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.

Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.

Journal: The Prostate

Published: August 11, 2023

Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).

Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).

Journal: Journal of cancer research and clinical oncology

Published: April 19, 2023

Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors.

Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors.

Journal: The British journal of radiology

Published: February 22, 2023

Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer.

Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer.

Journal: Head & neck

Published: December 20, 2022

Internal Guidelines for Reducing Lymph Node Contour Variability in Total Marrow and Lymph Node Irradiation.

Internal Guidelines for Reducing Lymph Node Contour Variability in Total Marrow and Lymph Node Irradiation.

Journal: Cancers

Published: December 14, 2022

The pattern of failure after Stereotactic Radiation Therapy (SRT) for oligo-metastases: predictive factors for poly-progression.

The pattern of failure after Stereotactic Radiation Therapy (SRT) for oligo-metastases: predictive factors for poly-progression.

Journal: Journal of cancer research and clinical oncology

Published: September 09, 2022

Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial.

Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial.

Journal: Current oncology (Toronto, Ont.)

Published: September 06, 2022

Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking.

Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking.

Journal: Radiation oncology (London, England)

Published: August 13, 2021

Showing 1-12 of 12

Last Updated: 09/26/2026